Endpoints News 23 feb 2026 FDA unveils long-awaited guidance on new pathway for individualized therapies
Endpoints News 23 feb 2026 AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago
Endpoints News 23 feb 2026 A federal experiment opens up a new market for digital health — if it works
Endpoints News 23 feb 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Endpoints News 22 feb 2026 MoonLake has 'confidence' ahead of FDA submission, discloses mid-stage arthritis win
Endpoints News 21 feb 2026 Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more